Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 might act as a tumour-suppressor gene, participating in negative feedback control of EGFR expression, which inhibits bladder cancer cells from growth, migration and invasion.
|
16978290 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.
|
23124613 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) are an inhibitor of receptor tyrosine kinases (RTKs) that was discovered in recent years, and many studies showed that LRIG1 is a tumor suppressor gene and may be related to tumor drug resistance.
|
25048475 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 is a negative regulator of growth factor signaling that has been shown to function as a tumor suppressor in vitro and in vivo in mice.
|
25180912 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 negatively regulates multiple receptor tyrosine kinases signaling including the epidermal growth factor receptor (EGFR) and is a proposed tumor suppressor.
|
25353163 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is a newly discovered tumor suppressor which involved in regulation of chemosensitivity in various human cancer cells.
|
26097540 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma.
|
29391393 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lrig1-specific deletion of the IL-17R adaptor Act1 or EGFR in mice impairs wound healing and reduces tumor formation.
|
30578323 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By partitioning the LRIG1 probes nearest exon 12/13, we confirm a breakpoint in the gene and show that gains and losses in the subregions differ by tumor and patient characteristics including race/ethnicity.
|
24879564 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our study indicates that LRIG1 represents a pleiotropic AR-regulated feedback tumor suppressor that functions to restrict oncogenic signaling from AR, Myc, ERBBs, and, likely, other oncogenic drivers.
|
31792211 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Estrogen stimulates Lrig1 accumulation and disruption of this induction enhances estrogen-dependent tumor cell growth, suggesting that Lrig1 functions as an estrogen-regulated growth suppressor.
|
21821674 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, RNAi-mediated silencing of LRIG1 alters EGFRvIII intracellular trafficking and leads to enhanced EGFRvIII expression, suggesting that loss of LRIG1 in tumors may contribute to a permissive environment for EGFRvIII overexpression, contributing to EGFRvIII oncogenesis.
|
18542056 |
2008 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, LRIG1 knockdown promoted the tumorigenic potential in vitro, which was manifested as increased proliferation, invasiveness, and migration as well as increased tumor size in vivo in the xenograft model.
|
30248341 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In all, 31 renal cell carcinomas (RCCs) were examined for expression of the potential tumour suppressor LRIG1 (formerly Lig-1) and the epidermal growth factor receptor (EGFR).
|
14520461 |
2003 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study the expression of LRIG1 (leucine rich repeats and immunoglobin-like domains 1) and its relation to EGFR (epidermal growth factor receptor) was examined in tumour samples and adjacent non-neoplastic tissues from 30 patients with colorectal cancer.
|
17851870 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the Swedish series, high expression of LRIG1 correlated with Gleason score, T-stage, tumor cell proliferation, vascular density and epidermal growth factor receptor (EGFR) phosphorylation.
|
21128282 |
2011 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the ability of LRIG1 to act as a triple threat: pan-ERBB negative regulator, intestinal stem cell marker and tumour suppressor.
|
23558895 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we evaluated the mRNA expression level of LRIG1-3 in human glioma cell lines and control-matched glioma tissues, characterized the sub-cellular localization of an LRIG3-GFP fusion protein, and analyzed the relationship between sub-cellular localization of LRIG1-3 and clinical parameters in 404 astrocytic tumors by immunohistochemistry.
|
16532360 |
2006 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased LRIG1 copy number was associated with increased levels of LRIG1 mRNA (two of three tumours) and protein (four of four tumours) in the tumours compared to matched non-neoplastic breast tissue, as assessed by RT-PCR and western blot analysis.
|
16168117 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been well established that LRIG1 negatively regulates multiple growth factor signaling pathways and is considered to be a tumor suppressor; however, the biological functions of LRIG2 remain largely unexplored.
|
30015847 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, LRIG1 negatively regulates receptor tyrosine kinases and functions as a tumor suppressor.
|
30429017 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
None of these genes, except LRIG1, showed expression in any of the tested tissues (including normal adult and fetal kidney, sporadic kidney tumours and tumour samples from the proband's family).
|
15016767 |
2004 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest LRIG1 as a tumor suppressor for head and neck cancers; LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers.
|
23624915 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive LRIG1 expression was definitely related with smaller tumor size (OR: 1.64, 95% CI=1.11-2.42), early tumor stage (OR: 3.67, 95% CI=1.87-7.21), well degree of differentiation (OR: 4.35, 95% CI=2.12-8.93) and negative recurrence (OR: 0.29, 95% CI=0.16-0.53).
|
30123358 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, in the search for endogenous negative regulators of EGF receptor, LRIG1 was cloned and characterized as a putative tumor suppressor gene often downregulated in various human tumors, including astrocytic tumors.
|
23337938 |
2013 |